Vertex flubbed data on Kalydeco-plus CF treatment

Blame it on a misinterpretation. Vertex Pharmaceuticals ($VRTX) had to revise data on its proposed combination therapy for cystic fibrosis after learning an initial analysis was faulty. The company is testing its new CF drug Kalydeco with an experimental therapy, hoping to boost response. Report